A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 25 Jan 2017

At a glance

  • Drugs TG 4010 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TIME
  • Sponsors Transgene
  • Most Recent Events

    • 25 Jan 2017 This trial was completed in Italy, according to European Clinical Trials Database.
    • 04 Jan 2017 Status changed from active, no longer recruiting to discontinued.
    • 07 Dec 2016 This trial was completed in Poland (end date: 2016-07-05), according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top